More than 1,000 affordable apartments could be coming to the Bronx thanks to a new development project
The project, spanning a jaw-dropping 1.2 million square feet, would rise 22 and 26 stories and sit across 19 tax lots currently home to low-rise warehouses (two of them vacant). Maddd Equities controls just over half of the site for now and it's still unclear if it plans to scoop up the rest.
Designed by Aufgang Architects, the complex goes well beyond just apartments. Plans call for 167,000 square feet of retail and community space, including a sports complex open to the public and local schools, located at the base of both buildings. There's also 1,000 square feet of light manufacturing space—think small-scale makers, a distillery or a woodworking shop.
But perhaps the smartest feature is what happens between the buildings: a landscaped pedestrian corridor that connects East 165th and East 164th Streets, plus an additional open space at the corner of Brook and 165th. Expect greenery, playgrounds, benches and a more welcoming streetscape in a section of the Bronx that's been sorely lacking investment.
While the site is currently zoned for manufacturing only, Maddd Equities is seeking a zoning change that would allow for both residential and commercial uses. The application kicks off a long public review process that includes a full Environmental Impact Statement.
If all goes according to plan, construction could kick off in 2027 and wrap by 2032.
Maddd Equities, led by CEO Jorge Madruga, has become a major player in the borough's redevelopment. The firm is behind several key projects, including the massive overhaul of the historic Kingsbridge Armory into a community hub called El Centro, which was recently approved by the Landmarks Preservation Commission and will include 450 affordable units.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
BioLargo Inc (BLGO) Q2 2025 Earnings Call Highlights: Strategic Moves Amid Revenue Challenges
Release Date: August 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BioLargo Inc (BLGO) has maintained its net stockholders' equity at around $6 million despite recent losses, showcasing effective capital management. The company has seen a significant increase in service revenues, rising from $300,000 to $1.2 million in the first half of the year. BioLargo Inc (BLGO) has successfully shipped its AEC unit to New Jersey, with validation work to be conducted by state and federal EPA, enhancing credibility. The company has raised $3.3 million in its subsidiary, Clyra Medical, indicating strong investor confidence in its potential. BioLargo Inc (BLGO) is pursuing a capital-conserving strategy by forming joint ventures for battery manufacturing, leveraging public funding and partnerships. Negative Points BioLargo Inc (BLGO) experienced a decline in revenue, with $3 million in the recent quarter compared to $5 million in the same period last year. The company faces uncertainty with its partner Ikigai and Pooph, impacting cash flow and financial forecasting. There is a significant delay in the commercialization of Clyra's wound care product, raising concerns about execution timelines. BioLargo Inc (BLGO) has increased debt obligations, primarily related to Clyra's preparation for product launch. The company is operating under financial pressure due to reduced cash flow from Pooph sales, necessitating cautious financial management. Q & A Highlights Warning! GuruFocus has detected 7 Warning Signs with BLGO. Q: Can you provide any additional insight into the challenges and successes to the barriers to entry for the salinity battery? A: Dennis Calvert, CEO, explained that the primary challenges include technical proof of claim, scaling up manufacturing, and regulatory hurdles. The company has achieved significant technical milestones and is working on scaling up production. Regulatory barriers are relatively low, focusing mainly on safety data and UL certification. The company is confident in its technology and is working towards proving its claims and securing partnerships. Q: Will BioLargo be funding the cost to build battery factories? Will you be involved in designing and building the factories? A: Dennis Calvert, CEO, stated that BioLargo will not be funding the factories directly. Instead, they will act as a vendor, providing engineering services, project management, and technology transfer. The factories will be financed through partnerships, public funding, and other financial arrangements, allowing BioLargo to focus on leveraging its core competencies. Q: What is the latest on New Jersey and the AEC project? A: Dennis Calvert, CEO, reported that the AEC unit has been shipped and is being set up in Lake Stockholm. The state and federal EPA will participate in validation work, which is crucial for future customer demonstrations. The company is excited about this significant milestone and will announce the go-live date soon. Q: How can you be so confident about Clyra given that it's taken so long? A: Dennis Calvert, CEO, expressed confidence in Clyra due to recent investments of $3.3 million and the technical prowess of their invention. The company is preparing for a significant product launch with strong partnerships in place. They aim to complete third-party testing and FDA paperwork by the end of the year, targeting a Q1 launch. Q: Do you have insight on Pooph's operations as far as advertising spend, the number of stores that they're in? A: Dennis Calvert, CEO, mentioned limited insight into Pooph's operations, making it difficult to forecast. However, he noted that Pooph had previously achieved a $50 million run rate and was in 40,000 stores. The company remains optimistic about Pooph's potential but is cautious due to uncertainties. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
20 minutes ago
- Yahoo
Grupo de Inversiones Suramericana SA (GIVSY) Q2 2025 Earnings Call Highlights: Strong Profit ...
Controlling Net Profit: COP1.2 trillion, up 34% compared to the same period last year. Operating Income: COP14.7 trillion, a 5% increase year-over-year. Operational Profit: COP2.7 trillion, up 13% from the previous year. Return on Equity: 11.7% over the last 12 months. Net Profit per Stock: COP6,000, a compound annual growth of 16% since 2019. Premiums Issued (Insurance): COP9.4 billion, a 3.1% increase. Technical Result (Insurance): COP1.2 trillion, up 10%. Net Profit (SURA Asset Management): COP600 billion, a 42% increase. Assets Under Management (AUM): COP781 billion, a 15% increase. Revenue from Commissions: COP2.1 trillion, up 9.4% in constant exchange rates. Net Profit (Grupo Cibest): COP3.5 trillion, up 14%. Equity Profitability (Grupo Cibest): 17.5% for the quarter. Dividends Expected: COP2.2 billion for the year. Warning! GuruFocus has detected 7 Warning Sign with GIVSY. Release Date: August 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Grupo de Inversiones Suramericana SA (GIVSY) reported a controlling net profit of COP1.2 trillion for the first half of 2025, up 34% compared to the same period last year. The company's strategic spin-off process has resulted in a simpler structure, increased share liquidity, and higher stock capitalization, making it more attractive to institutional investors. Shareholders have seen significant appreciation in their investments, with common and preferred stocks increasing by 65% and 93%, respectively, since the spin-off. The company has a diversified financial services platform operating in over 10 countries, serving 76 million clients, which provides resilience and flexibility. Grupo SURA's financial services companies contributed COP1.8 billion to the results of the first six months of 2025, a 17% increase compared to 2024. Negative Points The casualty insurance segment experienced a 4% decrease in premiums issued, primarily due to the contraction of mandatory transit accident insurance in Colombia and increased price competition. The net profit for the casualty insurance segment significantly reduced compared to the previous year, driven by higher administrative expenses and restructuring costs. Grupo SURA's debt remains high at approximately COP7 billion, with plans to maintain this level by year-end, limiting financial flexibility. The company faces challenges in closing the gap between the fundamental value of its portfolio and market appreciation, despite efforts to increase visibility and liquidity. There is ongoing volatility in financial markets, which complicates predicting investment yields for the second half of the year, potentially impacting future profitability. Q & A Highlights Q: Considering the guidance for 2025 net profit was between COP1.7 trillion and COP1.9 trillion, and the results of the first semester, are you thinking about increasing the guidance? A: (Juan Esteban Tor, CFO) We see a pace of COP2 billion, and with the trends and observations in every company of the portfolio, this number is quite reachable. We have a good capability and are at that level for 2025. Q: How do you expect the evolution of the results, keeping in mind the pension reform? A: The results of protection have been evolving favorably. The company now has COP2 billion in AUMs, growing 12%. Revenue from commissions is growing double digits, and operating profit is growing above 40%. We are prepared to operationally work with the new parameters of the reform once it is in place. Q: How is the company planning to expand its insurance segment? A: (Juan Camilo Parra, Investment and Treasury Manager) Suramericana is focused on enhancing its value offer under two pillars: enhancing new business models and exploring underserved markets, such as Chile and Mexico, with health solutions. Q: What are you doing to close the gap between the common and preferred stock of Grupo SURA? A: (Ricardo Jaramillo Mejia, CEO) We aim to close the gap through profitable and efficient operations, increasing liquidity, floating, and eligibility of indexes. We have increased dividends and made the capital structure simpler, among other efforts. Q: What priorities does the group have to assign capital, and what can be expected from dividends in the future? A: We focus on debt reduction, increasing dividends, and investments. We moved from COP550 pesos per stock in 2019 to 1,500 now. Our priorities are to reduce debt and increase dividends, with investments left to Suramericana and SURA Asset Management. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
20 minutes ago
- Yahoo
Milestone Scientific Inc (MLSS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Driven ...
Revenue: $2.3 million for Q2 2025, a 25% increase driven by dental segment performance. International Revenue: $1 million for Q2 2025, up from $489,000 in Q2 2024. Medical Revenue: $32,000 for Q2 2025, an increase from $19,000 in Q2 2024. Gross Profit: $1.6 million for Q2 2025, an increase of $206,000 from Q2 2024. Selling, General and Administrative Expenses: $3 million for Q2 2025, up from $2.9 million in Q2 2024. Research and Development Expenses: $52,000 for Q2 2025, down from $352,000 in Q2 2024. Loss from Operations: $1.5 million for Q2 2025, a decrease from $1.8 million in Q2 2024. Cash and Cash Equivalents: $1.3 million as of June 30, 2025. Working Capital: Approximately $3.9 million with no long-term debt. Cash Flows Used in Operating Activities: $2.8 million for the six months ended June 30, 2025. Warning! GuruFocus has detected 6 Warning Signs with MLSS. Release Date: August 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Milestone Scientific Inc (MLSS) reported a 25% revenue growth in Q2 2025, reaching $2.3 million, primarily driven by the dental segment. The company secured Medicare Part B payment rate assignment under CPT code 0770T in multiple jurisdictions, enhancing reimbursement pathways for the CompuFlo Epidural System. International sales more than doubled, contributing significantly to the revenue increase, with international revenue accounting for 48% of total sales. The company has strengthened its leadership team with the appointment of Eric Hines as CEO and Jason Papes as Senior Vice President, Global Head of Sales and Marketing, both bringing extensive experience in scaling operations. Milestone Scientific Inc (MLSS) maintained a solid balance sheet with $1.3 million in cash and no long-term debt, indicating strong financial management. Negative Points Despite the Medicare Part B coverage, adoption of the CompuFlo system in the medical segment has been slow, with only 5 to 10 clinics actively using the product. Domestic dental sales were relatively flat, indicating challenges in growing the US market despite international success. The company reported a loss from operations of approximately $1.5 million for Q2 2025, although this was a decrease from the previous year. Research and development expenses decreased significantly, which could impact future innovation and product development. The company faces challenges with tariffs and international market dynamics, which could affect future growth and profitability. Q & A Highlights Q: Can you discuss the adoption of the CompuFlo system on the medical side, particularly with Medicare Part B coverage, and what steps are being taken to accelerate its adoption? A: Eric Hines, CEO: We currently have between 5 and 10 clinics using the product in the US. The focus is on reimbursement, collecting data, and ensuring doctors are reimbursed appropriately. We plan to invest in specialists to help with claims and data collection, focusing initially on a few clinics to confirm reimbursement processes before expanding further. Q: What are the plans for expanding the sales team under the new Head of Sales, Jason Papes? A: Eric Hines, CEO: Jason brings his prior distribution business, primarily focused in Texas. We are evaluating our current relationships with Axial and Shamrock. The focus will be on US-based sales, particularly in states where we have traction, and potentially hiring additional distribution as needed. Q: What drove the international revenue growth this quarter, and what percentage of total revenue did it represent? A: Keisha Harcum, VP, Finance: International revenue accounted for 48% of total revenue. Growth was driven by additional distributors, larger orders, and improved communication with distributors. The international business tends to be lumpy due to large orders from groups of customers. Q: How are tariffs affecting your international business, and what measures have you taken to mitigate their impact? A: Keisha Harcum, VP, Finance: Tariffs have not significantly impacted us. We have set up direct shipping from our warehouse in China to international partners and have sufficient inventory in the US to avoid tariff-related issues. Q: What is the strategy for expanding reimbursement coverage for the CompuFlo system? A: Eric Hines, CEO: The focus is on deepening relationships in regions with existing reimbursement, collecting data, and ensuring reimbursement processes are solid before expanding. We plan to engage Board members with expertise in reimbursement to assist in this effort. Q: Can you provide an update on the VA status and any progress in that area? A: Eric Hines, CEO: We are focusing on one VA vision in the eastern US to make progress. Each VA operates independently, so the strategy is to succeed in one area first. Neal Goldman, Chairman: Pricing is favorable for both instruments and disposables, and success in the VA could accelerate growth on the medical side. Q: What is the status of the Brazil market, and are there any plans to pursue it further? A: Neal Goldman, Chairman: Brazil remains a long-term potential, but there are no immediate developments due to recent tariffs and other challenges. The focus is on executing in existing markets before expanding to new ones like Brazil. Q: How are clinicians responding to the CompuFlo technology, and is there a plan to leverage their feedback for broader adoption? A: Eric Hines, CEO: We have an advisory group to gather insights from clinicians using the product. The focus is on understanding the pros and cons and collecting data to refine our approach before expanding to a broader market. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
